Cargando…

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists

This study was conducted to survey US pediatric specialists about administration of respiratory syncytial virus (RSV) immunoprophylaxis, communication patterns among physicians and parents, and barriers to access. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Pierre C., Parimi, Prabhu S., Domachowske, Joseph B., Friedman, Deborah M., Marcus, Michael G., Garcia, Daniel F., La Via, William V., Syed, Iqra A., Szabo, Shelagh M., McLaurin, Kimmie K., Kumar, Veena R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119619/ https://www.ncbi.nlm.nih.gov/pubmed/26746004 http://dx.doi.org/10.1177/0009922815621343

Ejemplares similares

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
por: Lee, Henry, et al.
Publicado: (2017)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?
por: Sáfadi, Marco Aurélio P.
Publicado: (2014)

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012
por: Doucette, Abigail, et al.
Publicado: (2016)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data
por: Arend, Rebecca C., et al.
Publicado: (2021)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Passive Broad-Spectrum Influenza Immunoprophylaxis
por: Berry, Cassandra M., et al.
Publicado: (2014)

AAV Vectored Immunoprophylaxis for Filovirus Infections
por: Rghei, Amira D., et al.
Publicado: (2020)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Development in Immunoprophylaxis against Rabies for Animals and Humans
por: Nandi, Sukdeb, et al.
Publicado: (2010)

Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy
por: Duthie, Malcolm S, et al.
Publicado: (2016)

Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination
por: Sanders, John W., et al.
Publicado: (2017)

Immunoprophylaxis in fish by injection of mouse antibody genes
por: Lorenzen, Niels, et al.
Publicado: (2000)

Review of companion animal viral diseases and immunoprophylaxis
por: Patel, J.R., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_gr60of6hradlg4uemcun9poq4d